European Commission approves Roche’s Evrysdi for babies under two months old with spinal muscular atrophy
European Commission approves Roche’s Evrysdi for babies under two months old with spinal muscular atrophy Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved the…
Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years
Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years Novartis today announced new long-term data from ORION-8, a Phase III open-label extension of ORION-9,…
Sandoz receives FDA approval for Tyruko first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
Sandoz receives FDA approval for Tyruko first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis Sandoz, a global leader in generic and biosimilar medicines, today announced that the…
Oman Health Exhibition and Conference 2023: Pioneering Healthcare
Oman Health Exhibition and Conference 2023: Pioneering Healthcare In alignment with the Oman Vision 2040 strategy that identifies thehealthcare sector as a pivotal industry for progression, the Oman Health Exhibition…
Lilly’s Retevmo®Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer
Lilly’s Retevmo®Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-531 study evaluating Retevmo…
Johnson & Johnson Announces Preliminary Results of Kenvue Inc. Exchange Offer
Johnson & Johnson Announces Preliminary Results of Kenvue Inc. Exchange Offer Johnson & Johnson (NYSE: JNJ) today announced that, based on preliminary results, its previously announced offer to its shareholders…
Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) announced…
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age Pfizer Inc. (NYSE:…
AMGEN TO DISCUSS APPLICATION FOR LUMAKRAS® (SOTORASIB) FOR THE TREATMENT OF KRAS G12C-POSITIVE NSCLC AT FDA ADVISORY COMMITTEE MEETING
AMGEN TO DISCUSS APPLICATION FOR LUMAKRAS® (SOTORASIB) FOR THE TREATMENT OF KRAS G12C-POSITIVE NSCLC AT FDA ADVISORY COMMITTEE MEETING Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs…
European Commission Approves Reduced Dosing Frequency for Janssen’s Bispecific Antibody TECVAYLI®▼ (teclistamab)
European Commission Approves Reduced Dosing Frequency for Janssen’s Bispecific Antibody TECVAYLI®▼ (teclistamab) The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted the approval…
Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma Merck (NYSE: MRK), known as MSD…
Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States
Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States Gilead Sciences, Inc. (Nasdaq: GILD) and Meharry Medical College, one…